Introduction {#Sec1}
============

The reproductive-cell cycle theory of aging postulates that the hormones that regulate reproduction act in an antagonistic pleiotropic manner to control aging via cell cycle signaling; they promote growth and development early in life to achieve reproduction but later in life, in a futile attempt to maintain reproduction, become dysregulated and drive senescence (Bowen and Atwood [@CR7]). Thus, the dysregulation of the hypothalamic--pituitary--gonadal (HPG) axis (endocrine dyscrasia) leads to altered (dyotic) signaling to somatic and reproductive tissues, driving re-entry of cells into the cell cycle. In post-mitotic, terminally differentiated cell types, such signaling leads to attempted, albeit incomplete, cell division resulting in cellular dysfunction and/or death. In tissues containing totipotent stem cells, cellular division is completed at an enhanced rate.

The theory predicts that the longer the HPG axis is maintained in equilibrium, the longer an organism will live. Support for the dysregulation of the HPG axis in regulating lifespan comes from both animal and human studies (Helle et al. [@CR25]; Horiuchi [@CR27]). The most frequently reported relationship between reproduction and post-reproductive survival in humans is between late reproduction and longevity, with advanced age at last reproduction associated with improved longevity (Helle et al. [@CR25], Appendix A). In this study, we examined a number of reproductive life traits to determine whether maintenance of the HPG axis predicts increased longevity. We find that later age of menopause is consistently associated with reduced mortality among women in the Wisconsin Longitudinal Study (WLS) and that no other reproductive parameter assessed significantly predicted mortality. These results suggest that reproductive and somatic senescence are tightly coupled in humans and that selection to reproduce later (or longer) would favor enhanced longevity. Our findings suggest that strategies designed to maintain the HPG axis in equilibrium will increase longevity.

Methods {#Sec2}
=======

Data {#Sec3}
----

The WLS design and history have been discussed in detail elsewhere (Hauser [@CR22]; Hauser and Willis [@CR23]; Sewell et al. [@CR63]). Briefly, the WLS sample was originally comprised of 10,317 men and women who graduated from Wisconsin high schools in 1957 (one third of all who graduated, the modal year of birth was 1939). These individuals were surveyed in 1964, 1975, 1992, 2004, and 2010 (current round).[1](#Fn1){ref-type="fn"} In addition to the focal respondents, the WLS began interviewing one randomly selected sibling of each graduate (when possible) starting in 1977 (were mainly born between 1929 and 1949). Since then the survey content has been broadly parallel for graduate and sibling participants.

The WLS provides a comprehensive record of social background, adolescent ability and aspirations, schooling, military service, family formation, labor market experiences, health, personality, and social and civic participation of the original respondents. Data for the current study come primarily from the 1993 and 2004 waves of the WLS when female reproductive health and menopause questions were added to the supplemental mail surveys. These data were augmented with National Death Index (NDI) and Social Security Death Master File (SSA) death records.

Sample and response rates {#Sec4}
-------------------------

The WLS has and continues to enjoy exceptional response rates. The WLS sample includes 5,326 female graduates (original sample) and 4,341 randomly selected female siblings (supplemental sample, from graduates of either gender).[2](#Fn2){ref-type="fn"} Of these, 7,344 were able to be located, alive, and sent a mail survey in the 1993 interview round. We take this as the base sample for computing response rates. A total of 5,827 (72%) sample members completed the mail survey. Notably, 276 of these cases (5%) were still menstruating at last contact and excluded from analysis. Data suitable for analysis were obtained for 5,034 (91%) cases.[3](#Fn3){ref-type="fn"}

Measures {#Sec5}
========

Longevity {#Sec6}
---------

Death was the primary outcome measure for this study. Death records were collected from two sources: (1) the NDI, a national registry of deaths from local and state reporting agencies with near complete coverage of domestic deaths, and/or (2) SSA, a death registry compiled by the Social Security Administration of Social Security beneficiaries. Records were first matched with the NDI. If a match was found using NDI confirming a death, the date of death was recorded. At the time of this study, NDI death information was available up through December 2008. To ascertain deaths after December 2008 or for records not in the NDI, we matched records with the SSA. Though SSA records may have somewhat lower coverage than NDI records, they were both more current (available through June 2010) and less likely to contain reporting errors for crucial matching information (e.g., social security number, date of birth). If a death match was found in the SSA, the date of death was recorded. Records not matching NDI, SSA, or WLS internal mortality records were presumed alive as of June 2010.

Reproductive traits {#Sec7}
-------------------

Data on menopause, number of live births, unilateral and bilateral oophorectomy, hysterectomy, and hormone replacement therapy (HRT) were collected. Age of menopause---approximated by age of last menstrual period---was constructed from a combination of several items, including age of last menstrual cycle, menstruation within the last 12 months, and age at time of survey. Menopause and reproductive health data (surgery, HRT, etc.) were primarily extracted from the 1993 survey and updated, if necessary, from information collected at follow-up in 2004. Number of live births was collected from rosters of children that were updated at each survey wave.

Other factors {#Sec8}
-------------

Other covariates investigated were year of birth, adolescent IQ, years of education, marital status, family income, smoking status, and body mass index (BMI).[4](#Fn4){ref-type="fn"} These were collected at baseline (1993) or from administrative records. See Table [1](#Tab1){ref-type="table"} for sample descriptive statistics.Table 1Sample descriptive statistics*N*/mean/%RangeSample  *N*5,034  Age at 1993 interview (SD)54.1 (4.14)35.7--77.8Deaths  *N* (%)439 (8.7%)  Age at death (SD)65.9 (6.89)51--91Reproductive parameters  Age of last period (SD)47.7 (7.08)21--65  Biological children (SD)2.8 (1.70)0--18  Any HRT (%)61.6%  Oophorectomy, one or both (%)28.2%Baseline and additional controls  Adolescent IQ (SD)102.7 (14.6)61--145  Years of education (SD)13.4 (2.12)2--21  Current smoker17.5%  Body mass index (SD)26.1 (5.16)10--83  Currently married80.0%  Median family income\$47,600−\$12,000--\$1,000,000

Analyses {#Sec9}
--------

We used a prospective analytic design. We estimated two sets of proportional hazards regressions predicting mortality risk, with and without covariates (Cox [@CR16]; SAS Institute [@CR62]).[5](#Fn5){ref-type="fn"} These types of models relate time-to-event data to a set of covariates and an underlying hazard function. These models included both right and left censoring; right censoring was used for post-survey survival, while left censoring was used to account for survival from age of last period to age at survey. We also used a robust standard error correction for sibling pairs.

Preliminary models included all the controls listed in other factors above. Non-significant controls were dropped from the final "adjusted" regressions presented below. The significant controls that were retained were (a) years of education, (b) smoking status, (c) BMI, and (d) marital status. Preliminary models also explored alternative specifications of age at last period (i.e., age groups) with similar findings.

Results {#Sec10}
=======

The proportional hazards regression models indicated that menopause significantly predicts mortality (see Table [2](#Tab2){ref-type="table"}). Unadjusted data indicated a 2.9% reduction in mortality for every year of later menopause. Adjusting for years of education, smoking status, BMI, and marital status modestly attenuated the reduction in mortality to 2.6%.Table 2Proportional hazards regression resultsHazard ratio*p*95% CIAge of menopause (years)Unadjusted0.971\<0.0010.959--0.983Adjusted^a^0.974\<0.0010.962--0.986^a^Adjusted for baseline education, smoking, BMI, and marital status

Estimated survival probabilities from these regressions are shown in Table [3](#Tab3){ref-type="table"} and plotted in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} between the ages of 50 and 90. The data were modeled to represent the majority of menopause ages in our sample (40--55 years), with other controls evaluated at their mean. These illustrate how increasing age at menopause is associated with increased probability of survival for both unadjusted and adjusted regression models. Women in our sample who reached menopause at 40 years of age had a 39% chance of surviving to age 90, while women who reached menopause at 55 years of age had a 53% chance of surviving to age 90 (based on adjusted regressions). For example, this reduction in mortality (between menopause at age 55 vs 40) translated into a life expectancy advantage over the 50-90 age range of 1.58 years (4.6%).Table 3Estimated survival probabilities from age 50--90 by age of last periodAge last periodEstimated survival to age^a^60 (%)70 (%)80 (%)90 (%)40 years9790793945 years9792814450 years9893834955 years98938553^a^Adjusted for baseline years of education, smoking status, BMI, and marital statusFig. 1Unadjusted survival probability curves for women aged between 50 and 90 whose last menstrual period occurred at 40, 45, 50, or 55 years of ageFig. 2Adjusted survival probability curves for women aged between 50 and 90 whose last menstrual period occurred at 40, 45, 50, or 55 years of age

However, other reproductive traits that we explored in preliminary work (unilateral or bilateral oophorectomy, number of biological children, and HRT) did not significantly contribute to predicting mortality and were not included in our final regressions. In other words, no other reproductive parameters assessed added to the prediction of longevity, with or without considering age of menopause. Thus, surgical and natural menopause at age 40, for example, resulted in identical survival probabilities. It is important to note, however, that number of biological children and HRT were significantly associated with age of menopause. That is, number of biological children was positively associated with age of menopause, while use of HRT was negatively associated with age of menopause. It is also important to note that preliminary simulations did not suggest that loss to follow-up or missing data would significantly alter our main findings.

Discussion {#Sec11}
==========

Our findings suggest that maintenance of HPG axis homeostasis is a predictor of mortality. Later age of last period consistently predicted reduced mortality (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}); even when adjusted for a number of additional covariates, the effect remained largely unchanged. We also found in our preliminary regressions that surgical and natural menopause resulted in identical survival probabilities, as might be expected given that both result in the dysregulation of the HPG axis.

These data fit within the biological and evolutionary framework of the reproductive-cell cycle theory of aging that posits the endocrine dyscrasia resulting from the loss of negative feedback by sex steroids and inhibins on hypothalamic and pituitary hormonal production is driving our senescent phenotype and ultimately mortality. Thus, factors that regulate the commencement (puberty), end (menopause, andropause, oophorectomy), or modulation of HPG axis homeostasis (pregnancy, lactation, amenorrhea, and HRT) might be predicted to regulate senescence (age-related diseases) and mortality. Below we discuss the evidence for each of these factors with respect to age-related disease incidence and longevity.

Age at menopause {#Sec12}
----------------

Previous studies, together with our current study, indicate that higher age at menopause is associated with prolonged female post-reproductive lifespan (Helle et al. [@CR25]; Cooper et al. [@CR15]; Jacobsen et al. [@CR31], [@CR32]; Johnston [@CR36], [@CR37]; Ossewaarde et al. [@CR48]; Snowdon et al. [@CR66]; van der Schouw et al. [@CR70]). The most frequently reported relationship between reproduction and post-reproductive survival in humans is between late reproduction and longevity, with advanced age at last reproduction being associated with improved longevity (Helle et al. [@CR25], Appendix A). In addition, delaying of an entire reproductive effort to later age covaries with the enhanced post-reproductive survival of mothers (Helle et al. [@CR24]). Conversely, early menopause induced by bilateral oophorectomy at the time of hysterectomy for benign disease is associated with an increased risk of morbidity and mortality (Parker and Manson [@CR51]; Parker et al. [@CR52]; Rivera et al. [@CR54], [@CR55]; Rocca et al. [@CR56]). Oophorectomy is not associated with increased survival at any age (Parker et al. [@CR52]). In this connection, it has been shown that experimental manipulation of germ cell number affects longevity. Transplantation of reproductively viable ovaries from young mice into senescent mice significantly extended lifespan (Cargill et al. [@CR12]).

Further evidence that reproductive endocrine dyscrasia lies at the heart of mortality is indicated by the relationship between the age at menopause and age-related diseases. In women with later menopause, there is a reduced risk for developing cardiovascular disease (de Kleijn et al. [@CR18]; van der Schouw et al. [@CR70]; Jacobsen et al. [@CR31]; Hu et al. [@CR29]; Ossewaarde et al. [@CR48]), calcifications in the aorta (Witteman et al. [@CR74]), atherosclerosis (Joakimsen et al. [@CR35]), cognitive decline (McLay et al. [@CR45]), and bone fractures (van Der Voort et al. [@CR71]). The risk of colorectal cancer also is decreased (van Wayenburg et al. [@CR72]), and despite an increase in death from uterine and ovarian cancer with increasing age at menopause, the net effect of later menopause is an increased lifespan (Ossewaarde et al. [@CR48]).

As might be expected, early reproductive endocrine dyscrasia, occurring naturally or induced by unilateral or bilateral oophorectomy in premenopausal women, is associated with increased risk of developing dementia, cognitive decline, stroke, fatal and non-fatal coronary heart disease, Parkinsonism, osteoporosis, hip fracture, lung cancer, depression, and anxiety (Parker and Manson [@CR51]; Parker et al. [@CR52]; Rivera et al. [@CR54], [@CR55]; Rocca et al. [@CR56]; Nappi et al. [@CR47]; Rocca et al. [@CR57]; Shuster et al. [@CR65]; Gleason et al. [@CR21]; Rocca et al. [@CR58], [@CR59], [@CR60], [@CR61]; Lisabeth et al. [@CR42]; Baba et al. [@CR4]; Koushik et al. [@CR40]). Indeed, the increased prevalence of cognitive disease in women correlates with the abrupt earlier loss of gonadal function (Jorm et al. [@CR38]; McGonigal et al. [@CR44]; Brookmeyer et al. [@CR10]; Gao et al. [@CR19]; Andersen et al. [@CR1]; Hy and Keller [@CR30]). Prospective cohort studies indicate that E~2~ replacement therapy reduces the incidence (Henderson et al. [@CR26]) and delays the onset of cognitive decline in women and men (Tang et al. [@CR68]; Kawas et al. [@CR39]; Paganini-Hill and Henderson [@CR49]; Baldereschi et al. [@CR5]). It should be noted that similar protection is not always afforded by the use of *non-physiological* estrogens such as conjugated equine estrogens (CEE) and *non-physiological* progestagens such as medroxyprogesterone (MPA; Shumaker et al, [@CR64]). This might explain the null finding in our study for HRT and longevity, since most subjects taking HRT in the US were prescribed either Premarin (CEE) or Prempro (CEE + MPA). Similarly, suppression of circulating gonadotropins (and sex steroids) with GnRH agonist therapy halves the risk of death from AD (Bowen et al. [@CR8]; D'Amico et al. [@CR17]), suggesting elevations in gonadotropins drive cognitive decline (Bryan et al. [@CR11]; Casadesus et al. [@CR13], [@CR14]). Indeed, it has been demonstrated that down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits in mice (Bryan et al. [@CR11]).

Breast and ovarian cancer are the only age-related diseases where risk decreases with early reproductive endocrine dyscrasia, i.e., following oophorectomy (Parker et al. [@CR52]). Conversely, early menarche, higher numbers of ovulatory cycles, nulliparity, and late menopause are associated with increased risk for female reproductive cancers (Gladwell [@CR20]; Parsa and Parsa [@CR53]).

Age at menarche {#Sec13}
---------------

Just as earlier endocrine dyscrasia results in increased mortality, so too early age at menarche (before age 12 years), is correlated with increased risk of cardiovascular morbidity and mortality and overall mortality in women (Lakshman et al. [@CR41]). Conversely, two recent studies have found a 4.5% and 2.4% reduced risk of overall mortality for each year later menarche occurs (Jacobsen et al. [@CR33], [@CR34]). However, it is not clear if later age at menarche decreases risk of cardiovascular morbidity and mortality, per se, or if later age of menarche operates through later age of menopause as suggested by our results. Since earlier menarche might be associated with earlier menopause, with later menarche associating with later menopause, these data indicate that maintaining the HPG axis in equilibrium longer, for example, will decrease the risk of morbidity and mortality.

Partial re-establishment of the HPG axis with HRT {#Sec14}
-------------------------------------------------

The most compelling evidence in humans for reproductive endocrine dyscrasia regulating longevity comes from epidemiological studies of estrogen replacement therapy use after menopause. Partial balancing of the HPG axis with estrogen therapy (decreasing gonadotropin/GnRH production) extends longevity. Over 15 studies have demonstrated a reduction in the risk of mortality in those taking estrogen replacement therapies (reviewed in Paganini-Hill et al. [@CR50]). These studies consistently show a 20% to 50% decrease in mortality among users of estrogens. Recently, Paganini-Hill et al. ([@CR50]) reported increased longevity even in older users of post-menopausal estrogen therapy. There is considerable evidence that physiological hormone replacement therapies also delay the onset, halt the progression of, and even reverse the course of age-related diseases including heart disease, cerebrovascular disease (stroke), Alzheimer's disease, cancer, and osteoporosis (Atwood and Bowen [@CR3]). Thus, partial rebalancing of the HPG axis following menopause and during andropause via exposure to sex steroids increases longevity. Although there is mounting evidence that the elevations in gonadotropins promotes age-related diseases (Bowen et al. [@CR9]; Wilson et al. [@CR73]; Bryan et al. [@CR11]; Atwood and Bowen [@CR3]; Sun et al. [@CR67]), gonadotropins are of course downregulated by sex steroids (and GnRH agonists/antagonists). Thus, either the maintenance of sex steroid concentrations or the suppression of gonadotropin concentrations using sex steroids and/or GnRH agonists/antagonists would be expected to delay age-related diseases and extend longevity.

In animals, re-establishment of the negative feedback loops in the HPG axis of post-reproductive mice (22 months of age) following transplantation of reproductively viable ovaries from young mice (3 months of age) has been demonstrated to extend lifespan by up to 40% (Cargill et al. [@CR12]; Mason et al. [@CR43]). Gonad manipulation in model organisms provides strong evidence for a direct link between reproduction and longevity (Arantes-Oliveira et al. [@CR2]; Muller et al. [@CR46]). In the hermaphroditic worm *Caenorhabditis elegans*, neonatal ablation of the gonadal germ line cells while leaving the somatic gonad intact results in increased life span, but removal of the entire gonad yielded no change in life span (Hsin and Kenyon [@CR28]). Ablation of the germ line must be prior to germ line stem cell proliferation for lifespan extension to occur (Arantes-Oliveira et al. [@CR2]). However, no extension of lifespan was found following ablation of the germ line in *Drosophila melanogaster* (Barnes et al. [@CR6]). Characterization and quantitation of the endocrine signals in these animal models might help explain the discrepant results regarding longevity. In this respect, our own data indicate that suppression of GnRHR signaling in *C. elegans* significantly decreases reproduction 46% and prolongs lifespan 15% (23% at lower temperature) compared with wild-type worms (Vadakkadath Meethal et al. [@CR69]; Vadakkadath Meethal, and Atwood, unpublished data).

Limitations {#Sec15}
-----------

Our study is limited in a few ways. First, WLS participants are almost exclusively non-Hispanic white and grew up and have lived largely in Wisconsin. Second, while our preliminary work indicated that no other reproductive parameters were significantly associated with mortality, we cannot definitely rule out some other possible explanations for our findings, like pre-existing health problems. Third, our analyses relied exclusively on self-reported data for all predictors. Fourth, because of relatively low mortality in our sample and certain data limitations, we were not able to disaggregate our analyses by cause of death.

This research uses data from the Wisconsin Longitudinal Study (WLS) of the University of Wisconsin---Madison. Since 1991, the WLS has been supported principally by the National Institute on Aging (AG-9775, AG-21079, and AG-033285), with additional support from the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation, and the Graduate School of the University of Wisconsin---Madison. A public use file of data from the Wisconsin Longitudinal Study is available from the Wisconsin Longitudinal Study, University of Wisconsin---Madison, 1180 Observatory Drive, Madison, Wisconsin 53706 and at <http://www.ssc.wisc.edu/wlsresearch/data/>. The opinions expressed herein are those of the authors. This material is the result of work supported with the use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent the views of the Department of Veterans Affairs or the US Government. This is Geriatrics Research, Education and Clinical Center VA paper \# 2011--21.

Other than a nominal \$10 payment included in the 2004 mail survey, WLS respondents have never been reimbursed for participation.

Siblings were randomly selected from rosters of siblings ascertained during the 1975 graduate telephone interviews. However, some graduates declined to provide contact information for selected siblings. This number represents the number of female selected siblings regardless of whether contact information was obtained and should be interpreted as the maximum possible female sibling sample.

The primary reasons for incomplete data were individual item refusal and/or unclassifiable responses.

Global self-reported health was excluded as a predictor as menopause induces changes in global health.

We explored other analytic approaches, including predicting 5-year survival using logistic regression, with similar results.
